首页> 外国专利> IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

机译:融合至免疫球蛋白重链恒定区异二聚体(异二聚体FC)和组成相同的药物成分的IL-21(异二聚体FC融合IL-21)

摘要

The present invention relates to: a heterodimer fusion protein (heterodimeric Fc-fused protein) containing first and second Fc regions of an immunoglobulin heavy chain constant region pair and in which IL-21 is bound to the N-terminus and/or C-terminus of the first and/or second Fc region(s), and characterized in that CH3 domains of the first and second Fc regions are modified such that the formation of a heterodimer can be promoted; and a pharmaceutical composition containing the heterodimeric Fc-fused protein. When the immunoglobulin heavy chain constant region heterodimeric Fc-fused protein according to the present invention is used, the in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein can be remarkably increased.
机译:本发明涉及:异二聚体融合蛋白(异二聚体Fc融合蛋白),其包含免疫球蛋白重链恒定区对的第一和第二Fc区,并且其中IL-21结合至N端和/或C端。第一和/或第二Fc区的特征在于,第一和第二Fc区的CH3结构域被修饰,从而可以促进异二聚体的形成;以及含有异二聚体Fc融合蛋白的药物组合物。当使用根据本发明的免疫球蛋白重链恒定区异二聚体Fc融合蛋白时,包含在异二聚体Fc融合蛋白中的IL-21的体内半衰期可以显着增加。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号